Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“The proportion of stage I NSCLC is now well over 50% in the VA as of 2026, unmatched by any other healthcare system in the US. The proportion of NSCLC diagnosed as stage I is soaring in the VA while it is only barely rising in other healthcare systems across the US.
If all insurance systems achieved the unadjusted stage distribution seen in the VA, an additional 45,684 pts would be diagnosed with stage I and 65,933 fewer stage IV. Data reported by the St Louis VA thoracic surgery research team in 2024.”
Title: Early-Stage Lung Cancer in the Era of Lung Cancer Screening: Veterans Health Administration Outperforms Other Insurance Models
Authors: Nikki E. Rossetti, Daniel B. Eaton Jr., Steven Tohmasi, Brendan T. Heiden, Martin W. Schoen, Yan Yan, Ana A. Baumann, Su-Hsin Chang, Theodore S. Thomas, Mayank R. Patel, Daniel Kreisel, Ruben G. Nava, Whitney S. Brandt, Bryan F. Meyers, Benjamin D. Kozower, Varun Puri
Read The Full Article
Other articles featuring Lung Cancer on OncoDaily.